GSK
EquityGSK plc
Health Care · Drug Manufacturers - General
$56.66
+56.66 (+0.00%)
Open
N/A
Day Range
$56.29 - $57.03
52W Range
$32.38 - $61.70
Volume
2M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity
7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| A | Agilent Technologies, Inc. | $120.24 | N/A | 0.83% | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.60 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $59.95 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $234.95 | N/A | 2.83% | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.68 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.26 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $23.06 | N/A | - | +0.00% |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
www.gsk.com →🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+7.6%
3Y CAGR
-0.1%
5Y CAGR
N/A
10Y CAGR
N/A
5-Year Dividend Projection
| Year | Conservative | Base | Optimistic |
|---|
Based on historical CAGR. Not a guarantee of future dividends.
View Full Projection →Loading financial data...
Revenue & Earnings
No financial statement data available for GSK.